公开(公告)号：US12077536B2

公开(公告)日：2024-09-03

申请号：US17750821

申请日：2022-05-23

申请人： BEIGENE, LTD.

发明人： Yunhang Guo ,  Hai Xue ,  Zhiwei Wang ,  Hanzi Sun

IPC分类号： A61K31/496 ,  A61K31/438 ,  A61P35/00 ,  C07D403/12 ,  C07D405/14 ,  C07D471/04 ,  C07D471/14 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61P35/00 ,  C07D403/12 ,  C07D405/14 ,  C07D471/14 ,  C07D519/00

摘要： Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

公开(公告)号：US12066429B2

公开(公告)日：2024-08-20

申请号：US16913376

申请日：2020-06-26

申请人： National University Corporation Tokyo Medical and Dental University ,  Nippon Zoki Pharmaceutical Co., Ltd.

发明人： Hiroshi Asahara ,  Tomoki Chiba ,  Kentaro Abe

IPC分类号： C12N15/11 ,  C12N15/10 ,  C12N15/113 ,  C12N15/63 ,  G01N33/50

CPC分类号： G01N33/5023 ,  C12N15/1086 ,  C12N15/113 ,  C12N15/63 ,  C12N2310/14 ,  C12N2310/18 ,  C12N2320/10 ,  C12N2320/50 ,  G01N2500/02 ,  G01N2500/10

摘要： Provided are an expression inhibitor of an inflammation promoting factor based on the discovery of a new factor influencing the expression amount/level of an inflammation promoting factor, and a development tool therefor. Provided are also a diagnostic agent and a diagnosis method for immune diseases, inflammatory diseases, painful conditions and similar. More specifically provided are: an expression inhibitor of an inflammation promoting factor containing at least one kind of inhibitor selected from the group consisting of RBMS2 expression inhibitor and RBMS2 function inhibitor; a screening method using as an indicator the expression or the function of RBMS2; an expression cassette useful for the method; as well as a diagnostic agent containing a product detection agent for RBMS2 gene expression and disease detection method using as an indicator RBMS2 gene expression amount/level.

公开(公告)号：US12043667B2

公开(公告)日：2024-07-23

申请号：US16864481

申请日：2020-05-01

申请人： Inhibrx Biosciences, Inc.

发明人： Lucas Rascon ,  Angelica Sanabria ,  John C. Timmer ,  Brendan P. Eckelman

IPC分类号： C07K16/28 ,  A61K39/00 ,  C07K16/46 ,  C12N15/63 ,  A61K45/06

CPC分类号： C07K16/2851 ,  C07K16/468 ,  C12N15/63 ,  A61K2039/505 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/565

摘要： Provided herein are VHH-containing polypeptides that bind CLEC12a. Uses of the VHH-containing polypeptides are also provided.

公开(公告)号：US12037385B2

公开(公告)日：2024-07-16

申请号：US17346534

申请日：2021-06-14

申请人： Genentech, Inc.

发明人： Vishva Dixit ,  Robert F. Kelley ,  Marissa L. Matsumoto

IPC分类号： G01N33/53 ,  C07K14/47 ,  C07K16/18 ,  C12N15/10 ,  G01N33/68

CPC分类号： C07K16/18 ,  C07K14/4702 ,  C12N15/1037 ,  G01N33/68 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  G01N2333/4703 ,  G01N2440/36

摘要： The invention provides anti-polyubiquitin antibodies and methods of using the same.

公开(公告)号：US12016836B2

公开(公告)日：2024-06-25

申请号：US18168128

申请日：2023-02-13

申请人： Lapix Therapeutics, Inc.

发明人： Anas M. Fathallah ,  Scott D. Larsen ,  Abdulraouf Ramadan

IPC分类号： A61K31/198 ,  A61K9/00 ,  A61K9/08 ,  A61K31/357 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/472 ,  A61K47/40 ,  A61P25/28 ,  A61P37/06 ,  C07C235/34 ,  C07D213/65 ,  C07D217/02 ,  C07D235/06 ,  C07D319/18

CPC分类号： A61K31/198 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/357 ,  A61K31/4184 ,  A61K31/44 ,  A61K31/472 ,  A61K47/40 ,  A61P25/28 ,  A61P37/06 ,  C07C235/34 ,  C07D213/65 ,  C07D217/02 ,  C07D235/06 ,  C07D319/18

摘要： Provided herein are compounds and their pharmaceutically acceptable salts, lipid particles comprising such compounds or pharmaceutically acceptable salts thereof and compositions of the foregoing that can be used to reduce immune intolerance in a subject, for example, to treat autoimmune disorders, or in combination with an antigenic therapy, such as a protein or gene therapy, to improve the efficacy of the antigenic therapy. The compounds have the following structural formula:




wherein values for the variables (e.g., Ring A, L, R1, R2, R3, m) are as described herein.

公开(公告)号：US12012459B2

公开(公告)日：2024-06-18

申请号：US17818106

申请日：2022-08-08

申请人： Inhibrx, Inc.

发明人： John C. Timmer ,  William Crago ,  Kyle Jones ,  Katelyn Willis ,  Florian Sulzmaier ,  Bryan Becklund ,  Brendan P. Eckelman

IPC分类号： C07K16/28 ,  A61K35/17 ,  A61P35/00 ,  C12N15/85

CPC分类号： C07K16/2875 ,  A61K35/17 ,  A61P35/00 ,  C12N15/85 ,  C07K2317/569 ,  C12N2015/8518

摘要： Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.

公开(公告)号：US12005056B2

公开(公告)日：2024-06-11

申请号：US16982107

申请日：2019-03-14

申请人： Helsinn Healthcare SA

发明人： Claudio Giuliano ,  Claudio Pietra ,  Silvina Garcia Rubio ,  Angelo Guainazzi ,  Marielle Martinez-Loi

IPC分类号： A61K31/4468

CPC分类号： A61K31/4468

摘要： The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1-methyl-1-(1,3, 3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.

公开(公告)号：US11993636B2

公开(公告)日：2024-05-28

申请号：US17061155

申请日：2020-10-01

申请人： Sanofi

发明人： Gary J. Nabel ,  Chih-Jen Wei ,  Heather Kamp ,  Ronnie Wei ,  Kurt Swanson

IPC分类号： C07K14/20 ,  C12N15/10

CPC分类号： C07K14/20 ,  C12N15/102

摘要： This disclosure relates to antigenic OspA polypeptides and their use in eliciting antibodies against OspA. Also disclosed are antigenic polypeptides comprising an OspA polypeptide and a ferritin protein.

公开(公告)号：US11969418B2

公开(公告)日：2024-04-30

申请号：US17151954

申请日：2021-01-19

申请人： Genzyme Corporation

发明人： Meehyung Cho ,  Timothy J. Turner ,  Erik Wallstroem

IPC分类号： A61K31/4545 ,  A61K31/437 ,  A61P25/00 ,  A61P25/28

CPC分类号： A61K31/4545 ,  A61P25/28

摘要： This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors for treatment of subjects with relapsing multiple sclerosis.

公开(公告)号：US11965165B2

公开(公告)日：2024-04-23

申请号：US18063972

申请日：2022-12-09

申请人： Intellia Therapeutics, Inc.

发明人： Arti Mahendra Prakash Kanjolia ,  Shobu Odate ,  Jessica Lynn Seitzer ,  Reynald Michael Lescarbeau ,  Walter Strapps

IPC分类号： A61P25/28 ,  C12N9/22 ,  C12N15/10 ,  C12N15/113 ,  A61K48/00 ,  C12N15/11

CPC分类号： C12N15/113 ,  A61P25/28 ,  C12N9/22 ,  C12N15/102 ,  A61K48/00 ,  A61K48/0091 ,  C12N15/111 ,  C12N2310/20 ,  C12N2310/321 ,  C12N2800/80

摘要： Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.